Exenatide
Also known as: AC-2993, Bydureon, Bydureon BCise, Byetta, Exenatide, Exendin-4 synthetic, Exendin‑4, LY2148568
Source Exenatide at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Exenatide is an approved, subcutaneously administered GLP‑1 receptor agonist used to improve blood glucose control in adults with type 2 diabetes. It also produces modest weight loss and, in cardiovascular outcome trials, has been linked to reductions in major adverse cardiovascular events, mortality, heart‑failure admissions, and kidney disease progression.
Mechanism of Action
Exenatide mimics the endogenous incretin hormone GLP‑1, binding to the GLP‑1 receptor on pancreatic beta‑cells. This enhances glucose‑dependent insulin secretion, suppresses inappropriate glucagon release, slows gastric emptying and reduces appetite. The net effect is lower post‑prandial glucose, modest weight reduction, and downstream cardiometabolic benefits.
What the Research Shows
Systematic reviews and meta‑analyses of cardiovascular outcome trials, including the EXSCEL study of exenatide, show GLP‑1 receptor agonists lower major adverse cardiovascular events by about 12% and reduce cardiovascular death, stroke, myocardial infarction, all‑cause mortality, heart‑failure hospitalisations and a composite kidney outcome. A network meta‑analysis reported that extended‑release exenatide lowered all‑cause mortality in high‑risk patients. A weight‑loss review classified exenatide as causing mild weight loss (<3 % of baseline weight). A 2025 pooled analysis of 99,599 patients confirmed mortality and MACE reductions across GLP‑1 RAs, with increased gastrointestinal and gallbladder adverse events but no rise in pancreatitis or neoplasms. Evidence derives from multiple randomized trials and large meta‑analyses, though direct head‑to‑head data for exenatide are limited.
Reported Benefits
Exenatide improves glycaemic control, achieving clinically meaningful HbA1c reductions, and induces modest weight loss. In high‑risk cardiovascular populations it contributes to lower rates of major cardiovascular events, cardiovascular and all‑cause mortality, heart‑failure admissions, and progression of kidney disease. These benefits are supported by several randomized trials and high‑certainty meta‑analyses.
Limitations of the Evidence
The magnitude of weight loss with exenatide is smaller than that of newer GLP‑1 RAs. Direct comparative trials between exenatide and other agents are scarce, leading to reliance on subgroup or pooled analyses. Heterogeneity in trial designs, dosing regimens and patient populations introduces uncertainty about the exact size of cardiovascular benefit for exenatide alone. Long‑term safety beyond trial periods remains incompletely characterised.
Safety Considerations
The most common adverse effects are gastrointestinal (nausea, vomiting, diarrhoea), with meta‑analyses reporting a notable increase in GI disorders and a modest rise in gallbladder events. No increase in severe hypoglycaemia, pancreatitis, pancreatic cancer or stroke has been observed. As with all GLP‑1 RAs, exenatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2. Caution is advised in severe renal impairment, although some kidney‑protective signals have been noted.
How It Is Administered
Exenatide is supplied as a short‑acting formulation for twice‑daily subcutaneous injection and as an extended‑release formulation for once‑weekly injection (Bydureon). Injections are given into the abdomen, thigh or upper arm using the provided pen or prefilled syringe, according to the prescribed dosing schedule.
Routes of Administration
Goals & Uses
- Blood pressure reductionCardiovascularModerate
- Cardiovascular risk reductionCardiovascularModerate
- Beta-cell function preservationMetabolicLow
- Weight reductionMetabolicModerate
- Glycemic control in type 2 diabetesMetabolicHigh
- Glycaemic controlDiabetesHigh
Contraindications
- Personal or family history of medullary thyroid carcinomaOncologicHigh
- Severe gastrointestinal diseaseGastrointestinalModerate
- Type 1 diabetes mellitus or diabetic ketoacidosisMetabolicHigh
- Multiple endocrine neoplasia type 2OncologyHigh
- Medullary thyroid carcinomaOncologyHigh
- Severe renal impairment (eGFR <30 mL/min/1.73m²)RenalHigh
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)Genetic/EndocrineHigh
- History of hypersensitivity to exenatideImmunologicalHigh
Adverse Effects
- PancreatitisGastrointestinalRareInflammation of the pancreas
- HypoglycemiaMetabolicCommonAbnormally low blood glucose
- Injection site reactionsLocalCommon
- Hypoglycaemia (with sulfonylureas/insulin)MetabolicUncommon
- NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
- VomitingGastrointestinalCommonForceful expulsion of stomach contents
- Acute pancreatitisGastrointestinalRare
- DiarrhoeaGastrointestinalCommon
- DiarrheaGastrointestinalCommonLoose or frequent stools
Drug Interactions
- Antibiotics (time-sensitive oral agents)Low
- Oral contraceptivesLowDelayed gastric emptying may affect absorption timing
- InsulinModerateMay increase risk of low blood sugar
- DPP‑4 inhibitorsLow
- WarfarinModerate
- SulfonylureasModerateMay increase risk of low blood sugar
Population Constraints
- PregnancyReproductive SafetyRelative
- Pediatric patientsAgeRelative
- Pediatrics (<18 y)AgeAbsolute
- Elderly patients (≥75 years)AgeRelative
- Moderate renal impairment (eGFR 30–50 mL/min/1.73m²)RenalRelative
- History of pancreatitisGastrointestinalRelative
Regulatory Status
- European UnionApprovedApproved: type 2 diabetes mellitusSame indications as US.
- United StatesApprovedApproved: type 2 diabetes mellitusByetta (twice‑daily) and Bydureon (once‑weekly) formulations.
- United KingdomApprovedApproved: Type 2 diabetes mellitus as adjunct to diet, exercise, and other antidiabetic agentsApproved via legacy EMA process; MHRA oversight post-Brexit. NICE guidance supports use in specific patient subgroups meeting BMI/HbA1c criteria.
Approved in the US and EU for type 2 diabetes; extended‑release formulation (Bydureon) offers weekly dosing. Not approved for obesity in the US.
Evidence & Sources
- Journal ArticleHighKristensen SL, et al.2019-01-01T00:00:00.000000Z
- Journal ArticleHighTsapas A, et al.2020-01-01T00:00:00.000000Z
- Journal ArticleHighLazzaroni E, et al.2021-01-01T00:00:00.000000Z
- Journal ArticleHighAndreadis P, et al.2018-01-01T00:00:00.000000Z
- Journal ArticleHighNagendra L, et al.2023-01-01T00:00:00.000000Z
- Journal ArticleHighGalli M, et al.2025-01-01T00:00:00.000000Z
Frequently Asked Questions
How does exenatide differ from other GLP‑1 receptor agonists?
Exenatide is derived from exendin‑4 and is available in both twice‑daily and once‑weekly formulations. Compared with newer agents, it tends to produce milder weight loss and may have a slightly lower incidence of nausea, but direct head‑to‑head data are limited.
Can exenatide be used in patients with kidney disease?
Clinical trials have shown a modest reduction in kidney outcomes, but the drug is not recommended for patients with severe renal impairment without dose adjustment. Monitoring of renal function is advised.
What are the most common side effects?
Gastro‑intestinal symptoms—especially nausea, vomiting and diarrhoea—are the most frequent. Gallbladder‑related events occur more often than with placebo, while severe hypoglycaemia, pancreatitis and cancer have not been increased.
Does exenatide reduce heart‑failure risk?
Meta‑analyses of GLP‑1 receptor agonists, including trials of exenatide, report about a 9‑15 % reduction in hospitalisation for heart failure, suggesting a protective effect in high‑risk patients.
Is exenatide suitable for weight‑loss alone?
Exenatide produces modest weight loss (generally less than 3 % of body weight) and is approved for glycaemic control, not solely for obesity management. For larger weight reductions, newer GLP‑1 RAs may be preferred.
What is Exenatide?
Exenatide is an approved, subcutaneously administered GLP‑1 receptor agonist used to improve blood glucose control in adults with type 2 diabetes. It also produces modest weight loss and, in cardiovascular outcome trials, has been linked to reductions in major adverse cardiovascular events, mortality, heart‑failure admissions, and kidney disease progression.
What is Exenatide used for?
Exenatide is educationally associated with: Blood pressure reduction, Cardiovascular risk reduction, Beta-cell function preservation, Weight reduction, Glycemic control in type 2 diabetes, Glycaemic control. Educational only — not medical advice.
How is Exenatide administered?
Recorded routes of administration: Subcutaneous.
What are the potential side effects of Exenatide?
Reported adverse effects include: Pancreatitis, Hypoglycemia, Injection site reactions, Hypoglycaemia (with sulfonylureas/insulin), Nausea, Vomiting, Acute pancreatitis, Diarrhoea, Diarrhea. This list is not exhaustive — consult a qualified clinician.
Who should avoid Exenatide?
Recorded contraindications: Personal or family history of medullary thyroid carcinoma, Severe gastrointestinal disease, Type 1 diabetes mellitus or diabetic ketoacidosis, Multiple endocrine neoplasia type 2, Medullary thyroid carcinoma, Severe renal impairment (eGFR <30 mL/min/1.73m²), Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), History of hypersensitivity to exenatide. Consult a qualified clinician before use.